



(51) International Patent Classification:

A61K 31/4709 (2006.01) *A61P 31/14* (2006.01)
A61K 31/506 (2006.01) *A61K 45/06* (2006.01)
A61K 31/7056 (2006.01)

(21) International Application Number:

PCT/EP2011/066567

(22) International Filing Date:

23 September 2011 (23.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/388,253 30 September 2010 (30.09.2010) US

(71) Applicant (for all designated States except US):

BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOECHER, Wulf**

[DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE). **HAEFNER, Carla** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE). **KUKOLJ, George** [CA/CA]; Boehringer Ingelheim (Canada) Ltd., 2100 rue Canard, Laval, Québec H7S 2G5 (CA).

(74) Agents: **HAMMANN, Heinz** et al.; Boehringer Ingelheim GmbH, Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: COMBINATION THERAPY FOR TREATING HCV INFECTION

(57) Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.

